Lamivudine for the treatment of HIV

被引：30

作者：

Kumar, Princy N. ^{[1
]}

Patel, Parul ^{[2
]}

机构：

[1] Georgetown Univ, Div Infect Dis, Washington, DC 20007 USA

[2] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2010年 / 6卷 / 01期

关键词：

antiretroviral therapy; HIV; lamivudine; nucleoside reverse transcriptase inhibitor; IMMUNODEFICIENCY-VIRUS-INFECTION; ZIDOVUDINE COMBINATION THERAPY; TENOFOVIR DISOPROXIL FUMARATE; CHRONIC HEPATITIS-B; CD4 CELL COUNTS; ANTIVIRAL ACTIVITY; INITIAL TREATMENT; RESISTANT VIRUS; NAIVE PATIENTS; ABACAVIR;

D O I：

10.1517/17425250903490418

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Lamivudine is a nucleoside reverse transcriptase inhibitor that is widely used for the treatment of HIV-1 infection in combination with other antiretrovirals. It is a highly effective agent that can be dosed once or twice daily due to its long intracellular half-life. it also has one of the best tolerability and long-term safety profiles among all antiretroviral agents and continues to be preferred as part of initial or subsequent combination therapy in HIV-infected patients.

引用

页码：105 / 114

页数：10

共 66 条

[21] The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: A review of North American (NUCA 3081) and European (NUCB 3001) trials [J].

Eron, JJ .

AIDS, 1996, 10 :S11-S19

[22] TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER [J].

ERON, JJ ;

BENOIT, SL ;

JEMSEK, J ;

MACARTHUR, RD ;

SANTANA, J ;

QUINN, JB ;

KURITZKES, DR ;

FALLON, MA ;

RUBIN, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1662-1669

[23] Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects [J].

Gallant, JE ;

Rodriguez, AE ;

Weinberg, WG ;

Young, B ;

Berger, DS ;

Lim, ML ;

Liao, QM ;

Ross, L ;

Johnson, J ;

Shaefer, MS .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (11) :1921-1930

[24]

*GLAXOSMITHKLINE, 2009, EP LAM PRESCR INF

[25] Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [J].

Gulick, RM ;

Mellors, JW ;

Havlir, D ;

Eron, JJ ;

Gonzalez, C ;

McMahon, D ;

Richman, DD ;

Valentine, FT ;

Jonas, L ;

Meibohm, A ;

Emini, EA ;

Chodakewitz, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :734-739

[26] Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection [J].

Gulick, RM ;

Ribaudo, HJ ;

Shikuma, CM ;

Lustgarten, S ;

Squires, KE ;

Meyer, WA ;

Acosta, EP ;

Schackman, BR ;

Pilcher, CD ;

Murphy, RL ;

Maher, WE ;

Witt, MD ;

Reichman, RC ;

Snyder, S ;

Klingman, KL ;

Kuritzkes, DR .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (18) :1850-1861

[27] Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection - A randomized controlled trial [J].

Gulick, Roy M. ;

Ribaudo, Heather J. ;

Shikuma, Cecilia M. ;

Lalama, Christina ;

Schackman, Bruce R. ;

Meyer, William A., III ;

Acosta, Edward P. ;

Schouten, Jeffrey ;

Squires, Kathleen E. ;

Pilcher, Christopher D. ;

Murphy, Robert L. ;

Koletar, Susan L. ;

Carlson, Margrit ;

Reichman, Richard C. ;

Bastow, Barbara ;

Klingman, Karin L. ;

Kuritzkes, Daniel R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (07) :769-781

[28] Antiretroviral treatment of adult HIV infection - 2008 recommendations of the International AIDS Society USA panel [J].

Hammer, Scott M. ;

Eron, Joseph J., Jr. ;

Reiss, Peter ;

Schooley, Robert T. ;

Thompson, Melanie A. ;

Walmsley, Sharon ;

Cahn, Pedro ;

Fischl, Margaret A. ;

Gatell, Jose M. ;

Hirsch, Martin S. ;

Jacobsen, Donna M. ;

Montaner, Julio S. G. ;

Richman, Douglas D. ;

Yeni, Patrick G. ;

Volberding, Paul A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (05) :555-570

[29] A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].

Hammer, SM ;

Squires, KE ;

Hughes, MD ;

Grimes, JM ;

Demeter, LM ;

Currier, JS ;

Eron, JJ ;

Feinberg, JE ;

Balfour, HH ;

Dayton, LR ;

Chodakewitz, JA ;

Fischl, MA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733

[30] A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter [J].

Hammer, SM ;

Katzenstein, DA ;

Hughes, MD ;

Gundacker, H ;

Schooley, RT ;

Haubrich, RH ;

Henry, WK ;

Lederman, MM ;

Phair, JP ;

Niu, M ;

Hirsch, MS ;

Merigan, TC ;

Blaschke, TF ;

Simpson, D ;

McLaren, C ;

Rooney, J ;

Salgo, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (15) :1081-1090

← 1 2 3 4 5 6 7 →